Alex Biese

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

Axi-cel led to durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.

Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.

Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

The delivery of palliative care through telehealth vs in-person visits was equally beneficial for patients with advanced non–small cell lung cancer.

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.

Patient care begins with the patient, and Deb Schrag, MD, MPH, has spent her career keeping them the main focus of improving oncologic outcomes.

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.

Positive changes in symptoms of anxiety and depression were reported in patients with cancer following the use of a cognitive behavioral stress management app.